Skip to main content
Premium Trial:

Request an Annual Quote

Serenex Signs Chemoproteomics Deal with Lilly

NEW YORK, Aug. 5 (GenomeWeb News) - Serenex said today that Eli Lilly would use its chemoproteomics technology in select drug discovery programs.

 

Lilly will have access to Serenex's Proteome Mining and Functional Proteome Fractionation technologies to screen GSK compounds against thousands of protein targets simultaneously.

 

According to Serenex, the companies will evaluate how these technologies impact the lead identification process.

 

Financial terms of the agreement were not provided.

 

This agreement follows similar ones announced in May with GlaxoSmithKline, and in September 2002 with Chiron.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.